Transposon Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.transposonrx.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
TPN-101 in Aicardi-Goutières Syndrome (AGS)
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Transposon Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05613868
- Locations
- 🇫🇷
Laboratory of Neurogenetics and Neuroinflammation Imagine Institute - INSERM U1163, Paris, France
🇮🇹Presidio Ospedale dei Bambini [Children's Hospital], Brescia, Italy
🇮🇹SST Fatebenefratelli Sacco, Milano, Italy
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
- Conditions
- Amyotrophic Lateral SclerosisFrontotemporal Dementia
- Interventions
- Drug: TPN-101, 400 mg/dayDrug: Placebo
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Transposon Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04993755
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸University of California Irvine - ALS & Neuromuscular Center, Orange, California, United States
🇺🇸UCSF Neurosciences Clinical Research Unit (NCRU), San Francisco, California, United States
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Drug: TPN-101, 200 mg/dayDrug: TPN-101, 100 mg/dayDrug: TPN-101, 400 mg/dayDrug: Placebo
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Transposon Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04993768
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸UC San Diego Altman Clinical And Translational Research Institute, La Jolla, California, United States
🇺🇸UCSF Neurosciences Clinical Research Unit (NCRU), San Francisco, California, United States